Immunostimulant In Situ Hydrogel Improves Synergetic Radioimmunotherapy of Malignant Glioblastoma Relapse Post?Resection

Tumor recurrence remains the major cause of management failure after surgical resection glioblastoma (GBM). Immunotherapy has potential to effectively eradicate tumors and trigger immune memory prevent tumor but not improve outcomes GBM patients. Here, an injectable, reactive oxygen species-degradable therapeutic hydrogel ([email protected]), capable sustained local release soluble PD-1 (sPD-1) stimulator interferon gene (STING) agonist ADU-S100 (ADU), is developed applied in a model. Adeno-associated virus serotype 9 employed stably express sPD-1 blocking PD-1/PD-L1 pathway. Concomitantly, released ADU activates STING pathway immunogenicity response therapy. This combined with radiotherapy (RT) promotes T cells infiltration restores effector function, which exhibits robust antitumor significantly suppresses growth. Moreover, [email protected] RT treatment can also induce long-term recurrence. As result, provides novel strategy for effective radioimmunotherapy relapse post-resection.